Loteprednol 0.25% (Eysuvis) for Dry Eye Disease

Date: May 17, 2021 Issue #:  1624Summary:  The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% (Eysuvis– Kala) for short-term treatment (≤2 weeks) of dry eye disease. It is the first ocular corticosteroid to be approved for this indication. Other formulations of loteprednol are approved for treatment of steroid-responsive ocular inflammatory conditions, inflammation after ocular surgery, and seasonal allergic conjunctivitis.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Alrex Cequa Cyclosporine Dry eye disease Eysuvis Inveltys Lacrisert lifitegrast Lotemax loteprednol Restasis Tobramycin Xiidra Zylet Source Type: research